ABSORPTION AND EXCRETION OF INTRAVENOUSLY INJECTED OLEANDOMYCIN IN N ORMAL ADULTS AND PATIENTS WITH IMPAIRED RENAL FUNCTION
スポンサーリンク
概要
- 論文の詳細を見る
Oleandomycin phosphate (Matromycin) 500 mg was injected intravenously by the drop infusion in just 1 hour to 7 healthy volunteers and 12 patients with to variable extent impaired renal function. Mean serum concentration reached the highest level at 1 hour after the biginning of inject ion in both volunteer group and patient group, it was in the first group 20. 9 ± 6. 1 mcg/ml, and 40. 9± 11. 4 mcg/m1 in the second group. After 9 hours, serum concentration became undetectable level in volunteer group.. Conversely, it was sustained at 2. 5±0. 3 mcg/ml in patient group.<BR>Mean urinary concentration in volunteer group was 438±27 0 mcg/ml, and 298 ± 97 mcg/ml in patient, group in first 1 hour, and then 61 ± 22 mcg/ml and 40± 11 mcg/ml in the urine collecting from 6th to 9th hour respectively. Average 9 hours urinary recovery rate was 24. 0± 5. 0% in volunteers and 1 3. 9 ± 3. 1% in patients.<BR>Oleandomy cin clearance value was 43. 4 ± 11. 5 ml/min. in volunteers, but in patients it was reduced depending upon the severity of impairement of renal function.<BR>The administration of Probenecid made the oleandomy cin serum level lowered and its clearance value notably elevated. This means that oleandomycin was markedly reabsorbed at renal tubulus, and Probenecid disturbed the reabsorption.<BR>The correlation of o leandomycin clearance values with values of renal function tests was discussed. The most excellent correlation was obserbed with FISHBERG's concentration test, especially its maximall urine osmolatities. PSP test '(15 minutes values), urine specific gravidites and creatinine clearance values had also good correlation.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.